Top 25 drug classes included in step therapy
Traditionally, pharmaceutical step therapy ensured the use of themost appropriate and clinically sound drug therapy for patientswith specific diseases or conditions. More recently however, steptherapy has been used as a cost containment tool by health plansand hospitals alike.
Traditionally, pharmaceutical step therapy ensured the use of the most appropriate and clinically sound drug therapy for patients with specific diseases or conditions. More recently however, step therapy has been used as a cost containment tool by health plans and hospitals alike.
Step therapy promoted through the use of online claims edits, prior authorization or implementation of approved guidelines, allows the payer to promote the use of proven and cost-effective therapy prior to the use of more costly treatments, according to Alexander M. Gilderman, PharmD, vice president of Ventegra, a La Jolla, Calif.-based contracting service organization focused on the delivery of transparent pharmaceutical services.
From a managed care executive perspective, the step therapy modality allows for tight control of product usage within any step therapy class of drugs. "This approach somewhat guarantees that patients will always receive the plan's preferred agent-resulting in cost control," Boone says. "Should a patient require a different agent because of failure of the preferred agent, the physician can always write for an alternative choice, and the plan then has the satisfaction of knowing that the increased cost was justified.
"Unlike locking out all but one product, the step therapy approach allows plans to say that they cover alternative drugs but simultaneously assures the plan that only patients who fail the preferred product will actually get an alternative," Boone continues.
Generic products are among the highly utilized therapeutic classes, Gilderman says. "The use of step therapy can mandate that generic products be utilized before a more costly branded product is prescribed," he says. "With the cost of branded products approaching $80 vs. $15 for generics, significant cost savings can be realized."
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
What Payers Need to Know As Retail Pharmacies Move Into Primary Care
September 6th 2023Healthcare beyond the doors of the doctor’s office has the potential to offer more care to more people. But payers need to think about how to ensure that care is consistent. Regardless of the setting, care decisions must be based on evidence-based content and supported with strong patient education.
Read More
